Use of a Point-of-Care Platelet Function Assay for the Prediction of Atherothrombotic Events

Use of a Point-of-Care Platelet Function Assay to Improve the Prediction of Atherothrombotic Events After Implantation of Drug-Eluting Stents: ASAN-VerifyNow Registry

1. To evaluate the role of VerifyNow test as prognostic marker in routine clinical practice using drug-eluting stents.
2. To determine the add-on-effect of VerifyNow test beyond on conventional risk factors (clinical, lesions, or procedural factors).
3. To compare the prognostic utility of VerifyNow test with several biomarkers.

Predictive role of a point-of-care assay (VerifyNow test) has not been well evaluated in large number of patients receiving drug-eluting stents as a routine practice.

In addition, additional predictive effect of a point-of-care assay, as compared to conventional clinical factors or other biomarkers, might be clinically interesting and important.

Inclusion Criteria:

• Consecutive patients with established coronary artery disease receiving PCI with stent implantation

Exclusion Criteria:

• Cardiogenic shock
• Patients using concomitant medication known to affect platelet function other than aspirin (i.e. nonsteroidal antiinflammatory agents, dipyramidole, upstream glycoprotein IIb/IIIa inhibitors)
• patients with a known platelet function disorder or a whole blood platelet count of less than 150000/μL.